OncoSec Medical: Falls as breast cancer study data fails to impress

OncoSec Medical Incorporated

13/12/2019 18:16

**  Immunotherapy developer's shares  ONCS.O  down 16.8% at
$2.00; set for worst day in nearly 7 months 
    ** Co reports interim data from study testing experimental
treatment TAVO to treat a type breast cancer in combination with
Merck & Co Inc's  MRK.N  Keytruda  urn:newsml:reuters.com:*:nPn6HQYtza
    ** Co presents data from 14 of 25 patients in study, 4 of
whom showed a rapid tumor reduction
    ** When some smaller immune-oncology cos report positive
data, the fact that it's interim data tends to weigh
disproportionately on their stocks, and they end up selling off,
says James Molloy, analyst at Alliance Global Partners
    ** Stock has fallen 68.12% this year 

 (Reporting by Gautami Khandke)
 ((Gautami.Khandke@thomsonreuters.com;))